Platelet biology and response to antiplatelet therapy in women: Implications for the development and use of antiplatelet pharmacotherapies for cardiovascular disease

Journal of the American College of Cardiology

Volumn 59, Issue 10, 2012, Pages 891-900

  Wang, Tracy Y ^a   Angiolillo, Dominick J ^b   Cushman, Mary ^c   Sabatine, Marc S ^d   Bray, Paul F ^e   Smyth, Susan S ^f   Dauerman, Harold L ^c   French, Patricia A ^g   Becker, Richard C ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF VERMONT   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

^f UNIVERSITY OF KENTUCKY   (United States)

^g Left Lane Communications ^*  (United States)

Author keywords

bleeding; inflammation; platelets; sex; thrombosis; women

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTICOAGULANT AGENT; C REACTIVE PROTEIN; CILOSTAZOL; CLOPIDOGREL; FIBRINOGEN RECEPTOR; PADGEM PROTEIN; PLACEBO; PRASUGREL; THIENOPYRIDINE DERIVATIVE; TICAGRELOR;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLEEDING; CARDIOVASCULAR RISK; DRUG DOSE COMPARISON; DRUG EFFICACY; FEMALE; HEART DEATH; HEART INFARCTION; HUMAN; IMMUNOMODULATION; INFLAMMATION; LOW DRUG DOSE; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; RISK REDUCTION; SEX DIFFERENCE; STROKE; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOSIS;

EID: 84863285492     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2011.09.075     Document Type: Review

References (81)

1. C. Kim, C.E. Fahrenbruch, V. Menon Enrollment of women in National Heart, Lung, and Blood Institute-Funded cardiovascular controlled trials fails to meet current federal mandates for inclusion J Am Coll Cardiol 52 2008 672 673
2. C. Melloni, J.S. Berger, T.Y. Wang Representation of women in randomized clinical trials of cardiovascular disease prevention Circ Cardiovasc Qual Outcomes 3 2010 135 142
3. World Health Organization (WHO) Women's Health: Key Facts Fact Sheet no. 334. Basel: WHO, November 2009 http://www.who.int/mediacentre/factsheets/fs334/ en/index.html Accessed July 8, 2010
4. J. Xu, K.D. Kochanek, S.L. Murphy, B. Tejada-Vera Deaths: final data for 2007 Natl Vital Stat Rep 57 2009 1 134
5. M.J. Hall, C.J. DeFrances, S.N. Williams, A. Golosinskiy, A. Schwartzman National Hospital Discharge Survey: 2007 summary Natl Health Stat Rep 29 2010 1 20
6. National Heart, Lung, and Blood Institute (NHLBI) Incidence and Prevalence: 2006 Chart Book on Cardiovascular and Lung Diseases May 2006 NHLBI Bethesda http://www.nhlbi.nih.gov/resources/docs/06-ip-chtbk.pdf Accessed June 6, 2011
7. American Heart Association Heart Disease and Stroke Statistics2011 Update 2011 American Heart Association Dallas, TX http://circ.ahajournals.org/cgi/ reprint/CIR.0b013e3182009701 Accessed March 28, 2011
8. P.A. Gurbel, R.C. Becker, K.G. Mann, S.R. Steinhubl, A.D. Michelson Platelet function monitoring in patients with coronary artery disease J Am Coll Cardiol 50 2007 1822 1834 (Pubitemid 350007957)
9. M. Johnson, E. Ramey, P.W. Ramwell Sex and age differences in human platelet aggregation Nature 253 1975 355 357
10. N. Faraday, P.J. Goldschmidt-Clermont, P.F. Bray Sex differences in platelet GPIIb-IIIa activation Thromb Haemost 77 1997 748 754 (Pubitemid 27182975)
11. K. Kurrelmeyer, L. Becker, D. Becker Platelet hyperreactivity in women from families with premature atherosclerosis J Am Med Womens Assoc 58 2003 272 277
12. J.D. Snoep, M. Roest, A.D. Barendrecht, P.G. De Groot, F.R. Rosendaal, J.G. Van Der Bom High platelet reactivity is associated with myocardial infarction in premenopausal women: a population-based case-control study J Thromb Haemost 8 2010 906 913
13. O. Eidelman, C. Jozwik, W. Huang Gender dependence for a subset of the low-abundance signaling proteome in human platelets Hum Genomics Proteomics 2010 2010 164906
14. D.M. Becker, J. Segal, D. Vaidya Sex differences in platelet reactivity and response to low-dose aspirin therapy JAMA 295 2006 1420 1427
15. A.R. Hobson, Z. Qureshi, P. Banks, N. Curzen Gender and responses to aspirin and clopidogrel: insights using short thrombelastography Cardiovasc Ther 27 2009 246 252
16. P.A. Gurbel, K.P. Bliden, E. Cohen Race and sex differences in thrombogenicity: risk of ischemic events following coronary stenting Blood Coagul Fibrinolysis 19 2008 268 275 (Pubitemid 351670410)
17. L. Badimon, R.F. Storey, G. Vilahur Update on lipids, inflammation and atherothrombosis Thromb Haemost 105 Suppl 1 2011 S34 S42
18. H.F. Langer, M. Gawaz Platelet-vessel wall interactions in atherosclerotic disease Thromb Haemost 99 2008 480 486 (Pubitemid 351549284)
19. R. Ross Atherosclerosisan inflammatory disease N Engl J Med 340 1999 115 126
20. P. Libby, D.I. Simon Inflammation and thrombosis: the clot thickens Circulation 103 2001 1718 1720 (Pubitemid 32291406)
21. P.M. Ridker, C.H. Hennekens, J.E. Buring, N. Rifai C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women N Engl J Med 342 2000 836 843 (Pubitemid 30165206)
22. M. Cushman, A.M. Arnold, B.M. Psaty C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: the Cardiovascular Health Study Circulation 112 2005 25 31 (Pubitemid 40962565)
23. D.I. Buckley, R. Fu, M. Freeman, K. Rogers, M. Helfand C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force Ann Intern Med 151 2009 483 495
24. K.L. Margolis, J.E. Manson, P. Greenland Women's Health Initiative Research Group Leukocyte count as a predictor of cardiovascular events and mortality in postmenopausal women: the Women's Health Initiative Observational Study Arch Intern Med 165 2005 500 508 (Pubitemid 40344380)
25. P.M. Ridker, J.E. Buring, N. Rifai Soluble P-selectin and the risk of future cardiovascular events Circulation 103 2001 491 495 (Pubitemid 32116231)
26. J.B. Muhlestein Effect of antiplatelet therapy on inflammatory markers in atherothrombotic patients Thromb Haemost 103 2010 71 82
27. M. Fisher, M. Cushman, V. Knappertz, G. Howard An assessment of the joint associations of aspirin and statin use with C-reactive protein concentration Am Heart J 156 2008 106 111
28. M.J. Quinn, D.L. Bhatt, F. Zidar Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention Am J Cardiol 93 2004 679 684 (Pubitemid 38338553)
29. D.J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease Diabetes 55 2006 780 784 (Pubitemid 43343236)
30. M.D. Tarantino, T.J. Kunicki, D.J. Nugent The estrogen receptor is present in human megakaryocytes Ann N Y Acad Sci 714 1994 293 296 (Pubitemid 24197806)
31. G. Khetawat, N. Faraday, M.L. Nealen Human megakaryocytes and platelets contain the estrogen receptor beta and androgen receptor (AR): testosterone regulates AR expression Blood 95 2000 2289 2296 (Pubitemid 30167727)
32. G.J. Wu, J.J. Lee, D.S. Chou Inhibitory signaling of 17β-estradiol in platelet activation: the pivotal role of cyclic AMP-mediated nitric oxide synthase activation Eur J Pharmacol 649 2010 140 149
33. S.B. Jones, D.B. Bylund, C.A. Rieser, W.O. Shekim, J.A. Byer, G.W. Carr α2-Adrenergic receptor binding in human platelets: alterations during the menstrual cycle Clin Pharmacol Ther 34 1983 90 96 (Pubitemid 13073309)
34. D.L. Yee, C.W. Sun, A.L. Bergeron, J.F. Dong, P.F. Bray Aggregometry detects platelet hyperreactivity in healthy individuals Blood 106 2005 2723 2729 (Pubitemid 41510746)
35. J.B. Braunstein, D.W. Kershner, P. Bray Interaction of hemostatic genetics with hormone therapy: new insights to explain arterial thrombosis in postmenopausal women Chest 121 2002 906 920 (Pubitemid 34251459)
36. M. Cushman, C. Legault, E. Barrett-Connor Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study Circulation 100 1999 717 722 (Pubitemid 29383641)
37. P.M. Ridker, C.H. Hennekens, N. Rifai, J.E. Buring, J.E. Manson Hormone replacement therapy and increased plasma concentration of C-reactive protein Circulation 100 1999 713 716 (Pubitemid 29383640)
38. J.E. Rossouw, M. Cushman, P. Greenland Inflammatory, lipid, thrombotic, and genetic markers of coronary heart disease risk in the Women's Health Initiative trials of hormone therapy Arch Intern Med 168 2008 2245 2253
39. E.J. Weiss, P.F. Bray, M. Tayback A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis N Engl J Med 334 1996 1090 1094 (Pubitemid 26120186)
40. A2 ) is a risk factor for bypass occlusion, myocardial infarction, and death Thromb Haemost 83 2000 404 407 (Pubitemid 30148352)
41. P.F. Bray Platelet glycoprotein polymorphisms as risk factors for thrombosis Curr Opin Hematol 7 2000 284 289 (Pubitemid 30637667)
42. P.F. Bray, T.D. Howard, E. Vittinghoff, D.C. Sane, D.M. Herrington Effect of genetic variations in platelet glycoproteins Ibα and VI on the risk for coronary heart disease events in postmenopausal women taking hormone therapy Blood 109 2007 1862 1869 (Pubitemid 46348181)
43. J.S. Berger, M.C. Roncaglioni, F. Avanzini, I. Pangrazzi, G. Tognoni, D.L. Brown Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials (erratum in JAMA 2006;295:2002) JAMA 295 2006 306 313
44. Antithrombotic Trialists' (ATT) Collaboration C. Baigent, L. Blackwell, R. Collins et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials Lancet 373 2009 1849 1860
45. ISIS-2 Collaborative Group Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2 Lancet 2 1988 349 360
46. M.J. Quinn, H.D. Aronow, R.M. Califf Aspirin dose and six-month outcome after an acute coronary syndrome J Am Coll Cardiol 43 2004 972 978 (Pubitemid 38352974)
47. R.J. Peters, S.R. Mehta, K.A. Fox CURE Trial Investigators Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study Circulation 108 2003 1682 1687 (Pubitemid 37243654)
48. S.R. Steinhubl, D.L. Bhatt, D.M. Brennan CHARISMA Investigators Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding Ann Intern Med 150 2009 379 386
49. T. Wolff, T. Miller, S. Ko Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force Ann Intern Med 150 2009 405 410
50. L.B. Goldstein, R. Adams, M.J. Alberts American Heart Association, American Stroke Association Stroke Council Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council (erratum in Circulation 2006;114:e617) Circulation 113 2006 e873 e923
51. J.S. Berger, D.L. Bhatt, C.P. Cannon The relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysis J Am Coll Cardiol 54 2009 1935 1945
52. S.D. Wiviott, E. Braunwald, C.H. McCabe Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015 (Pubitemid 350106708)
53. L. Wallentin, R.C. Becker, A. Budaj PLATO Investigators Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
54. D. Sibbing, W. Koch, D. Gebhard Cytochrome 2C19 (*)17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement Circulation 121 2010 512 518
55. J.L. Mega, S.L. Close, S.D. Wiviott Cytochrome p-450 polymorphisms and response to clopidogrel N Engl J Med 360 2009 354 362
56. E. Boersma, R.A. Harrington, D.J. Moliterno Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials Lancet 359 2002 189 198 (Pubitemid 34113814)
57. R.P. Giugliano, J.A. White, C. Bode EARLY ACS Investigators Early versus delayed, provisional eptifibatide in acute coronary syndromes N Engl J Med 360 2009 2176 2190
58. P.M. Ridker, N.R. Cook, I.M. Lee A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women N Engl J Med 352 2005 1293 1304
59. S. Subherwal, R.G. Bach, A.Y. Chen Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) bleeding score Circulation 119 2009 1873 1882
60. K.P. Alexander, A.Y. Chen, L.K. Newby Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) initiative Circulation 114 2006 1380 1387 (Pubitemid 44462663)
61. B. Ahmed, W.D. Piper, D. Malenka Significantly improved vascular complications among women undergoing percutaneous coronary intervention: a report from the Northern New England Percutaneous Coronary Intervention Registry Circ Cardiovasc Interv 2 2009 423 429
62. G.V. Moukarbel, J.E. Signorovitch, M.A. Pfeffer Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT trial Eur Heart J 30 2009 2226 2232
63. B. Ahmed, S. Lischke, L.A. Holterman, F. Straight, H.L. Dauerman Angiographic predictors of vascular complications among women undergoing cardiac catheterization and intervention J Invasive Cardiol 22 2010 512 516
64. L. Bowyer, M.A. Brown, M. Jones Vascular reactivity in men and women of reproductive age Am J Obstet Gynecol 185 2001 88 96 (Pubitemid 32681800)
65. D.J. Angiolillo, A. Fernndez-Ortiz, E. Bernardo Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted? J Invasive Cardiol 16 2004 169 174 (Pubitemid 38456448)
66. K.P. Alexander, A.Y. Chen, M.T. Roe Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes (erratum in JAMA 2006;295:628) JAMA 294 2005 3108 3116 (Pubitemid 43016802)
67. R. Iijima, G. Ndrepepa, J. Mehilli Profile of bleeding and ischaemic complications with bivalirudin and unfractionated heparin after percutaneous coronary intervention Eur Heart J 30 2009 290 296
68. A.J. Lansky, R. Mehran, E. Cristea Impact of sex and antithrombin strategy on early and late clinical outcomes in patients with non-ST-elevation acute coronary syndromes (from the ACUITY trial) Am J Cardiol 103 2009 1196 1203
69. C.L. Campbell, S.R. Steinhubl, W.C. Hooper Bleeding events are associated with an increase in markers of inflammation in acute coronary syndromes: an ACUITY trial substudy J Thromb Thrombolysis 31 2011 139 145
70. T.Y. Wang, L. Xiao, K.P. Alexander Antiplatelet therapy use after discharge among acute myocardial infarction patients with in-hospital bleeding Circulation 118 2008 2139 2145
71. D.W. Mudrick, A.Y. Chen, M.T. Roe Changes in glycoprotein IIb/IIIa inhibitor excess dosing with site-specific safety feedback in the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines (CRUSADE) initiative Am Heart J 160 2010 1072 1078
72. M.J. Price Monitoring platelet function to reduce the risk of ischemic and bleeding complications Am J Cardiol 103 Suppl A 2009 35A 39A
73. M.J. Price, P.B. Berger, P.S. Teirstein GRAVITAS Investigators Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial JAMA 305 2011 1097 1105
74. T. Cuisset, C. Frere, J. Quilici Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study J Am Cardiol Intv 1 2008 649 653
75. Y.H. Jeong, S.W. Lee, B.R. Choi Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study J Am Coll Cardiol 53 2009 1101 1109
76. Y. Han, Y. Li, S. Wang Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study Am Heart J 157 2009 733 739
77. D.P. Faxon, J.E. Freedman Facts and controversies of aspirin and clopidogrel therapy Am Heart J 157 2009 412 422
78. H.L. Dauerman, D.L. Bhatt, D.D. Gretler, P.A. French, S.S. Smyth, R.C. Becker 2009 Platelet Colloquium Participants Bridging the gap between clinical trials of antiplatelet therapies and clinical applications among elderly patients Am Heart J 159 2010 508 517
79. P.Y. Lee, K.P. Alexander, B.G. Hammill Representation of elderly persons and women in published randomized trials of acute coronary syndromes JAMA 286 2001 708 713 (Pubitemid 33010364)
80. E.S.H. Kim, V. Menon Status of women in cardiovascular clinical trials Arterioscler Thromb Vasc Biol 29 2009 279 283
81. E.L. Ding, N.R. Powe, J.E. Manson, N.S. Sherber, J.B. Braunstein Sex differences in perceived risks, distrust, and willingness to participate in clinical trials: a randomized study of cardiovascular prevention trials Arch Intern Med 167 2007 905 912 (Pubitemid 46762752)